Metarrestin (ML246) is an orally active and specific perinucleolar compartment (PNC) inhibitor that disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription. Metarrestin blocks metastatic development and extends survival in mouse cancer models.
[1] Kevin J Frankowski, et al. Sci Transl Med. 2018 May 16;10(441):eaap8307.
















